Stockreport

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

MapLight Therapeutics, Inc.  (MPLT) 
PDF Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for A [Read more]